Previous Close | 79.74 |
Open | 79.62 |
Bid | 79.82 x 900 |
Ask | 81.48 x 1100 |
Day's Range | 79.52 - 81.12 |
52 Week Range | 68.84 - 92.02 |
Volume | |
Avg. Volume | 6,324,101 |
Market Cap | 107.368B |
Beta (5Y Monthly) | 0.78 |
PE Ratio (TTM) | 25.67 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.76 (3.41%) |
Ex-Dividend Date | Mar 21, 2024 |
1y Target Est | N/A |
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.
According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues DUBLIN, IRELAND / ACCESSWIRE / April 19, 2024 / Americans overwhelmingly ...
Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live